News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
224,656 Results
Type
Article (5003)
Company Profile (17)
Press Release (219636)
Section
Business (82194)
Career Advice (461)
Deals (15041)
Drug Delivery (8)
Drug Development (19061)
Employer Resources (30)
FDA (3674)
Job Trends (3900)
News (120093)
Policy (7498)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (292)
Adcomms (3)
Allergies (9)
Alliances (14759)
ALS (19)
Alzheimer's disease (243)
Antibody-drug conjugate (ADC) (11)
Approvals (3689)
Artificial intelligence (39)
Autoimmune disease (2)
Automation (2)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (9)
Brain cancer (7)
Breast cancer (46)
Cancer (424)
Cardiovascular disease (20)
Career advice (391)
Career pathing (2)
CAR-T (29)
Cell therapy (100)
Cervical cancer (2)
Clinical research (15993)
Collaboration (161)
Compensation (145)
Complete response letters (2)
COVID-19 (301)
CRISPR (7)
C-suite (90)
Cystic fibrosis (16)
Data (484)
Depression (5)
Diabetes (37)
Diagnostics (2035)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (40716)
Editorial (1)
Employer branding (6)
Employer resources (31)
Events (37635)
Executive appointments (279)
FDA (3905)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (174)
Gene editing (15)
Generative AI (2)
Gene therapy (44)
GLP-1 (105)
Government (407)
Guidances (16)
Healthcare (5035)
Huntington's disease (1)
IgA nephropathy (3)
Immunology and inflammation (13)
Indications (6)
Infectious disease (316)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7814)
IRA (3)
Job creations (1120)
Job search strategy (360)
Kidney cancer (6)
Labor market (4)
Layoffs (100)
Leadership (4)
Legal (2330)
Liver cancer (17)
Lung cancer (50)
Lymphoma (27)
Management (10)
Manufacturing (45)
MASH (26)
Medical device (3855)
Medtech (3856)
Mergers & acquisitions (7416)
Metabolic disorders (111)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (1)
Neuroscience (331)
NextGen: Class of 2025 (1674)
Non-profit (727)
Northern California (865)
Now hiring (2)
Obesity (50)
Opinion (30)
Ovarian cancer (17)
Pain (12)
Pancreatic cancer (13)
Parkinson's disease (21)
Partnered (4)
Patents (21)
Patient recruitment (26)
Peanut (5)
People (24507)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4768)
Phase II (6944)
Phase III (5535)
Pipeline (516)
Policy (4)
Postmarket research (625)
Preclinical (1863)
Press Release (66)
Prostate cancer (26)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (63)
Real estate (1872)
Recruiting (8)
Regulatory (5095)
Reports (14)
Research institute (300)
Resumes & cover letters (68)
Rett syndrome (2)
Schizophrenia (21)
Series A (25)
Series B (21)
Sickle cell disease (7)
Southern California (668)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (3)
Startups (1007)
Stomach cancer (1)
Supply chain (10)
United States (6647)
Vaccines (34)
Venture capitalists (2)
Webinars (4)
Weight loss (19)
Women's health (1)
Date
Today (83)
Last 7 days (256)
Last 30 days (920)
Last 365 days (10294)
2025 (2477)
2024 (11028)
2023 (13193)
2022 (18658)
2021 (19678)
2020 (18238)
2019 (13205)
2018 (10205)
2017 (10001)
2016 (9156)
2015 (12118)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (183)
Alabama (13)
Alaska (2)
Arizona (59)
Arkansas (1)
Asia (11430)
Australia (1600)
California (1815)
Canada (663)
China (67)
Colorado (77)
Connecticut (90)
Delaware (27)
Europe (24416)
Florida (253)
Georgia (32)
Idaho (23)
Illinois (109)
India (5)
Indiana (59)
Iowa (1)
Japan (64)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (38)
Maryland (214)
Massachusetts (1461)
Michigan (84)
Minnesota (134)
Mississippi (1)
Missouri (21)
Montana (16)
Nebraska (12)
Nevada (22)
New Hampshire (15)
New Jersey (532)
New Mexico (5)
New York (451)
North Carolina (314)
North Dakota (2)
Northern California (865)
Ohio (53)
Oklahoma (5)
Oregon (3)
Pennsylvania (332)
Rhode Island (11)
South America (275)
South Carolina (4)
Southern California (668)
Tennessee (34)
Texas (215)
Utah (57)
Virginia (40)
Washington D.C. (8)
Washington State (160)
West Virginia (2)
Wisconsin (20)
224,656 Results for "ladrx corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
LadRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc., together with NantCell’s parent company ImmunityBio, Inc., have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017.
June 3, 2024
·
3 min read
Biotech Beach
LadRx Issues 2024 Update to Shareholders
LadRx Corporation issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.
January 9, 2024
·
5 min read
Press Releases
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
December 11, 2024
·
1 min read
Biotech Beach
LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced today that it has initiated a process to explore a range of strategic and financing alternatives, and provided updates.
March 15, 2023
·
5 min read
Business
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets.
June 22, 2023
·
4 min read
Policy
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
XOMA Corporation, the biotech royalty aggregator, announced that based upon the U.S. Food and Drug Administration’s acceptance of Zevra Therapeutics’ New Drug Application for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C, XOMA will make a $1 million milestone payment to LadRx.
January 11, 2024
·
4 min read
Deals
LadRx Announces Reverse Stock Split
LadRx Corporation today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares.
May 10, 2023
·
4 min read
Biotech Beach
LadRx Corporation Issues Corporate Update for 3Q22
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.
November 17, 2022
·
6 min read
Biotech Beach
CytRx Corporation Relaunches as LadRx Corporation
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
September 23, 2022
·
4 min read
Biotech Beach
LadRx Highlights Patent Issued for Its LADR Technology
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.
March 27, 2023
·
3 min read
1 of 22,466
Next